Source: Eur Respir J 2002; 20: 127-133



Rating:

Share or cite this content

Citations should be made in the following way:
Skov M., Main K.M., Sillesen I.B., Muller J., Koch C., Lanng S.. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20: 127-133

Member's Comments

No comment yet.

Related content which might interest you: Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA). Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J, 52 (3) 1801159; 10.1183/13993003.01159-2018 Year: 2018 Effectiveness of itraconazole and systemic steroids in the treatment of ABPA Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Treatment of chronic pulmonary aspergillosis by voriconazole compared with micafungin Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus Year: 2009 Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020 Year: 2020 Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Treatment of chronic necrotizing pulmonary aspergillosis (CNPA) with micafungin (MCFG) Source: Eur Respir J 2005; 26: Suppl. 49, 410s Year: 2005 Effect of itraconazole therapy on disease course in 3 cases of allergic bronchopulmonary mycosis presented as refractory asthma Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond Year: 2008 Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy Source: Eur Respir J 2005; 25: 324-328 Year: 2005 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006 Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids Source: Eur Respir J 2008; 32: 1047-1052 Year: 2008 The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005 Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011 Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma Source: Eur Respir J 2011; 37: 865-872 Year: 2011 Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016